Bryan, Garnier & Co has advised FSI on EUR 15 million investment in DBV Technologies
Share the transaction
Paris – March 28th, 2012 – Bryan, Garnier & Co, the independent pan-European investment bank focused on European growth companies, today announced it has advised FSI on its investment into DBV Technologies.
The Strategic Investment Fund (FSI) has invested EUR 15 million in DBV Technologies during its initial public offering on NYSE Euronext Paris. This investment allowed FSI to acquire a 12.6% stake in DBV Technologies. Bryan, Garnier & Co acted as financial advisor to FSI on this transaction.
For more information please contact:
Jean-Christophe Renondin – Managing Director – Corporate Finance / +33 1 56 68 75 04 / jcrenondin@bryangarnier.com
Raquel Pires – Analyst – Corporate Finance – + 33 1 56 68 75 38 | rpires@bryangarnier.com
About DBV Technologies
DBV Technologies is a French publicly owned company focused on the development of innovative products for the diagnosis and treatment of food allergies. Founded in 2002 by leading French pediatricians with funding from ANVAR, it is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies or for allergy diagnosis. DBV Technologies’ novel approach to food allergy diagnosis and treatment is focused on eliciting an immune response by targeting the antigen-presenting cells in the skin epidermis. The antigens (allergens) are delivered to the skin using DBV Technologies’ unique worldwide patented delivery system, VIASKIN®.
(http://www.dbv-technologies.com/)
About the FSI
Created in 2008, the FSI (Strategic Investment Fund) is a limited company in which Caisse des Dépôts has a 51% share, with the State holding 49%. FSI contributes through equity capital to French businesses whose projects create value and competitiveness for the economy. FSI acts as a minority shareholder, through involvement on its own or as a joint investor.